D.J.A. Eckland

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial

Manfred Westphal, Seppo Ylä‐Herttuala, John Martin et al. · The Lancet Oncology · 2013 · 240 citations

Medicine, Oncology, Pharmacology +15

Paradoxical responses of hypothalamic corticotropin-releasing factor (CRF) messenger ribonucleic acid (mRNA) and CRF-41 peptide and adenohypophysial proopiomelanocortin mRNA during chronic inflammatory stress.

Michael S. Harbuz, Richard Rees, D.J.A. Eckland et al. · Endocrinology · 1992 · 199 citations

Medicine, Endocrinology, Physiology +17

Inhibition of Hypothalamic Thyrotropin-Releasing Hormone Messenger Ribonucleic Acid during Food Deprivation*

N. G. Blake, D.J.A. Eckland, O Föster et al. · Endocrinology · 1991 · 172 citations

Life Sciences, Nutritional Sciences, Physiology +17

Clinical pharmacokinetics of pioglitazone

D.J.A. Eckland, Meindert Danhof · Experimental and Clinical Endocrinology & Diabetes · 2000 · 162 citations

Pharmacy, Pharmacokinetics, Pharmacology +17